Yossi Gilgun‐Sherki

Author

Yossi Gilgun‐Sherki

Also Known As

Gilgun-Sherki Yossi, Gilgun-Sherki, Y., N. Sasson, Y Gilgun-Sherki, Y Sherki, Yossi Gilgun-Sherki, Yossi Gilgun‐Sherki, Yossi Sherki

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Rabin Medical Center Tel Aviv University Teva Pharmaceuticals (Israel)Hebrew University of Jerusalem Northwestern University

About

Yossi Gilgun‐Sherki is an author at Rabin Medical Center specializing in medicine, neurology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	616
2	Social Sciences	3	3	168
3	Allergy	1	1	49
4	Cell Biology	1	1	133
5	Endocrinology	1	1	49

Yossi Gilgun‐Sherki

Publications

900

Citations

H-Index

Page 1

	Year	Citations
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease1This manuscript is based on a poster presented at the Brain Research Interactive Symposium on “Neuropeptides at the Millennium”, Miami, October 1999.1 Daniel Offen, Yossi Gilgun‐Sherki, Eldad Melamed, Brain Research Neurodegenerative DiseasesNeuropeptidesNeurobiology Of Disease“ NeuropeptidesSynaptic Signaling	2000	141
A low molecular weight copper chelator crosses the blood–brain barrier and attenuates experimental autoimmune encephalomyelitis Daniel Offen, Yossi Gilgun‐Sherki, Yael Barhum, Journal of Neurochemistry ImmunologyImmune RegulationInnate ImmunityReactive Oxygen SpeciesOxidative Stress	2004	133
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis Yossi Gilgun‐Sherki, Hana Panet, Eldad Melamed, Brain Research Autoimmune DiseaseNeurological DisorderMedicineImmunodeficienciesImmunology	2003	106
Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis Yossi Gilgun‐Sherki, Hana Panet, Vered Holdengreber, Neuroscience Research InflammationGlatiramer Acetate TreatmentC57/bl MiceAutoimmune DiseaseImmunology	2003	75
A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease Merav Bahat‐Stroomza, Yossi Gilgun‐Sherki, Daniel Offen, European Journal of Neuroscience	2005	71
Safety, pharmacokinetics, and pharmacodynamics of TV‐1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects Orit Cohen‐Barak, Jacqueline Wildeman, Jeroen van de Wetering, The Journal of Clinical Pharmacology Healthy SubjectsPsychotropic MedicationPharmacotherapyButyrylcholinesterase TreatmentAddiction Medicine	2014	62
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial Maria Fleseriu, Alexander Dreval, Irina Bondar, The Lancet Diabetes & Endocrinology AllergyInjectable Somatostatin ReceptorClinical TrialsEndocrinologyMedicine	2021	49
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial Tjalf Ziemssen, Ovidiu Băjenaru, Adriana Carrá, Journal of Neurology	2014	42
Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence Yossi Gilgun‐Sherki, Rom E. Eliaz, David J. McCann, Drug and Alcohol Dependence	2016	39
The CB<sub>1</sub> Cannabinoid Receptor Agonist, HU‐210, Reduces Levodopa‐Induced Rotations in 6‐Hydroxydopamine‐Lesioned Rats Yossi Gilgun‐Sherki, Eldad Melamed, Raphael Mechoulam, Pharmacology & Toxicology	2003	38

Page 1